SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Space Exploration Technologies Corp., doing business as SpaceX, operates as an aerospace manufacturer, launch service provider, and satellite communications company. It is building the integrated hardware and software infrastructure of the future across space, connectivity, and AI. The firm designs, manufactures, launches, and operates products and services built on cutting-edge technologies, including the rockets and spacecraft. The company was founded by Elon Reeve Musk in 2002 and is headquartered in Starbase, TX.

Space Exploration Technologies Corp. - Ordinary Shares - Class A

SpaceX

SpaceXs Q3 earnings beat expectations, with traders highlighting rapid growth in its AI-computing business and Starlink. Bulls celebrated the results and ambitious growth outlook, while skeptics questioned the valuation and heavy infrastructure spending and noted the stocks muted reaction.

Super Micro Computer, Inc. engages in the distribution and manufacture of information technology solutions and other computer products. Its products include twin solutions, MP servers, GPU and coprocessor, MicroCloud, AMD solutions, power supplies, SuperServer, storage, motherboards, chassis, super workstations, accessories, SuperRack and server management products. The company was founded by Charles Liang, Yih-Shyan Liaw, Sara Liu, and Chiu-Chu Liu Liang in September 1993 and is headquartered in San Jose, CA.

Super Micro Computer Inc

Super Micros preliminary quarterly update sharply raised its revenue outlook and projected higher gross margins, citing AI-platform demand. Traders largely welcomed the surprise as evidence of strong AI-server demand and a possible boost to the broader AI trade, while others questioned whether the gains would hold amid persistent concerns about management, execution, and volatile price action.

Netflix, Inc. engages in providing entertainment services. It also offers activities for leisure time, entertainment video, video gaming, and other sources of entertainment. It operates through the United States and International geographic segments. The company was founded by Marc Randolph and Wilmot Reed Hastings on August 29, 1997 and is headquartered in Los Gatos, CA.

Netflix Inc.

Netflix Inc

Netflixs quarterly results were broadly solid, but softer forward guidanceincluding a reduced advertising outlook and lower expected cash flowhas driven a sharp post-earnings selloff amid concerns about slowing growth. Traders are split between expecting further downside and viewing the drop as an overreaction to guidance despite the earnings beat.

NVIDIA Corp. engages in the design and manufacture of computer graphics processors, chipsets, and related multimedia software. It operates through the following segments: Graphics Processing Unit (GPU) and Compute & Networking. The Graphics segment includes GeForce GPUs for gaming and PCs, the GeForce NOW game streaming service and related infrastructure, Quadro and NVIDIA RTX GPUs for enterprise workstation graphics, virtual GPU, or vGPU, software for cloud-based visual and virtual computing, automotive platforms for infotainment systems, and Omniverse Enterprise software for building and operating metaverse and 3D internet applications. The Compute & Networking segment consists of Data Center accelerated computing platforms and end-to-end networking platforms including Quantum for InfiniBand and Spectrum for Ethernet, NVIDIA DRIVE automated-driving platform and automotive development agreements, Jetson robotics and other embedded platforms, NVIDIA AI Enterprise and other software, and DGX Cloud software and services. The company was founded by Jen Hsun Huang, Chris A. Malachowsky, and Curtis R. Priem in April 1993 and is headquartered in Santa Clara, CA.

NVIDIA Corp

Reports of large Chinese orders for Nvidias export-compliant RTX PRO 5500 GPUs are fueling discussion, with traders pointing to strong demand but noting supply constraints and uncertainty over how much Nvidia can deliver. The stocks muted response has frustrated bulls, while others remain cautious amid broader concerns about AI spending, financing risks and recent weakness in chip stocks.

Tesla, Inc. engages in the design, development, manufacture, and sale of electric vehicles and energy generation and storage systems. It operates through the Automotive and Energy Generation and Storage segments. The Automotive segment includes the design, development, manufacture, sale, and lease of electric vehicles as well as sales of automotive regulatory credits. The Energy Generation and Storage segment is involved in the design, manufacture, installation, sale, and lease of solar energy generation, energy storage products, and related services and sales of solar energy systems incentives. The company was founded by Jeffrey B. Straubel, Elon Reeve Musk, Martin Eberhard, and Marc Tarpenning on July 1, 2003 and is headquartered in Austin, TX.

Tesla Inc

Tesla is drawing attention ahead of its Q3 earnings report, with traders weighing the recent rebound against concerns about margins and whether results or guidance can justify high expectations. Speculative SpaceX merger chatter adds to the discussion, while views remain split between a continued rally and a post-earnings pullback.

Intel Corp. engages in the design, manufacture, and sale of computer products and technologies. It delivers computer, networking, data storage, and communications platforms. The firm operates through the following segments: Client Computing Group (CCG), Data Center and AI (DCAI), Intel Foundry Services (IFS), and All Other. The CCG segment consists of platforms designed for notebooks, 2-in-1 systems, desktops, tablets, phones, wireless and wired connectivity products, and mobile communication components. The DCAI segment delivers solutions to cloud service providers and enterprise customers, along with silicon devices for communications service providers and high-performance computing customers. The IFS segment refers to full stack solutions created from the foundry industry ecosystem. The All Other segment represents results from other non-reportable segments and corporate-related charges. The company was founded by Robert Norton Noyce and Gordon Earle Moore on July 18, 1968, and is headquartered in Santa Clara, CA.

Intel Corp.

Intel Corp

Intels volatile rebound after a sharp semiconductor selloff has drawn attention to JPMorgans upgrade to Neutral and the companys turnaround prospects. Bulls point to potential foundry wins and improving execution, while skeptics question the valuation and durability of the bounce; earnings are also in focus.

SELLAS Life Sciences Group, Inc. is a clinical stage biopharmaceutical company, which engages in the development and commercialization of immunotherapeutic for cancer indications. Its product pipeline includes galinpepimut-S. The company was founded by Angelos M. Stergiou on April 3, 2006 and is headquartered in New York, NY.

SELLAS Life Sciences Group Inc

SELLAS is drawing attention as traders anticipate the 80th death event that triggers final analysis of its Phase 3 REGAL trial of GPS; the last disclosed count was 78, and the event has not been confirmed in the discussion. The CEOs next chapter remarks have also fueled speculative buyout talk, while others caution that the sharp price moves have occurred without new clinical results.

Nebius Group NV is a technology company that provides infrastructure and services to AI builders worldwide. It offers Nebius AI, an AI-centric cloud platform provides full-stack infrastructure, including large-scale GPU clusters, cloud services, and developer tools. The company also operates through specialized brands: Toloka AI, which partners in data for generative AI development; TripleTen, an edtech platform focused on re-skilling individuals for tech careers; and Avride, which develops autonomous driving technology. Nebius Group was founded by Elena Kolmanovskaya, Ilya Segalovich, Mikhail Fadeev, and Arkady Volozh in 1989 and is headquartered in Amsterdam, the Netherlands.

Nebius Group N.V. - Ordinary Shares - Class A

Nebius Group N.V. 

Nebius is being swept up in a sharp selloff across AI infrastructure and neocloud stocks, as traders worry that heavy data-center spending, debt and financing costs may outpace returns; CoreWeaves debt concerns and Gartners warning about neocloud consolidation add to the pressure. Bulls argue Nebius has stronger finances and can benefit from sustained demand for AI compute, while bears question whether the buildout can be funded profitably; traders are also watching upcoming earnings and hyperscaler capex commentary.

iShares Trust - iShares Russell 2000 Index Fund

iShares Russell 2000 ETF

IWM is drawing attention after a small-cap rebound amid rotation away from tech, with traders pointing to easing yields and reports of a possible U.S.Iran deal that helped lift broader markets. The deal remains unconfirmed, and the community is split between seeing a relief rally and viewing the move as a fragile, headline-driven bounce.

Intuitive Surgical, Inc. engages in the provision of robotic-assisted surgical solutions and invasive care through a comprehensive ecosystem of products and services. Its products include Da Vinci Surgical and Ion Endoluminal systems. The company was founded by Frederic H. Moll, John Gordon Freund, and Robert G. Younge in November 1995 and is headquartered in Sunnyvale, CA.

Intuitive Surgical Inc

ISRG is in focus after a strong Q3 earnings beat was met with a sharp selloff, as traders weighed a proposed antitrust settlement and a narrower full-year da Vinci procedure-growth outlook. Some see the reaction as excessive given continued business growth, while others view the outlook and settlement as reasons for caution.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Microsoft Corporation

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

MRNA On Track To Be September's No. 2 S&P 500 Stock — But These 5 Smaller Health Care Names Did Even Better

Equity

Five smaller stocks with market caps above $100 million beat MRNA’s monthly gain: INDP rose 249%, CYPH 124%, MNOV 85%, GRAL 58% and SRZN 53%.

Surrozen (NASDAQ:SRZN) CEO Craig Parker Sells 4,524 Shares

Surrozen, Inc. (NASDAQ:SRZN - Get Free Report) CEO Craig Parker sold 4,524 shares of the firm's stock in a transaction that occurred on Monday, May 4th. The shares were sold at an average price of $33.33, for a total transaction of $150,784.92. Following the completion of the transaction, the chief...

Surrozen (NASDAQ:SRZN) COO Charles Williams Sells 2,036 Shares

Surrozen, Inc. (NASDAQ:SRZN - Get Free Report) COO Charles Williams sold 2,036 shares of the company's stock in a transaction that occurred on Monday, May 4th. The shares were sold at an average price of $33.33, for a total value of $67,859.88. Following the transaction, the chief operating officer...

Yang Li Sells 1,584 Shares of Surrozen (NASDAQ:SRZN) Stock

Surrozen, Inc. (NASDAQ:SRZN - Get Free Report) VP Yang Li sold 1,584 shares of the business's stock in a transaction on Monday, May 4th. The stock was sold at an average price of $33.33, for a total transaction of $52,794.72. Following the completion of the transaction, the vice president directly...

Surrozen (SRZN) Projected to Post Quarterly Earnings on Friday

Surrozen (NASDAQ:SRZN) will be releasing its Q1 2026 earnings before the market opens on Friday, May 8. (View Earnings Report at...

Surrozen, Inc. (NASDAQ:SRZN) Sees Large Growth in Short Interest

Surrozen, Inc. (NASDAQ:SRZN - Get Free Report) saw a significant increase in short interest during the month of April. As of April 15th, there was short interest totaling 434,571 shares, an increase...

Surrozen, Inc. (NASDAQ:SRZN) Receives Average Rating of "Moderate Buy" from Brokerages

Surrozen, Inc. (NASDAQ:SRZN - Get Free Report) has been given an average recommendation of "Moderate Buy" by the five ratings firms that are presently covering the company, Marketbeat reports. One analyst has rated the stock with a sell recommendation, three have assigned a buy recommendation and...

Avita Medical (RCEL) Soars 14.1%: Is Further Upside Left in the Stock?

Avita Medical (RCEL) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in the near term.

Surrozen (SRZN) Surges 5.9%: Is This an Indication of Further Gains?

Surrozen (SRZN) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions may not translate into further price increase in the near term.

Surrozen (NASDAQ:SRZN) Upgraded at Wall Street Zen

Wall Street Zen upgraded Surrozen from a "sell" rating to a "hold" rating in a report on Saturday...

Surrozen, Inc. is a clinical stage biotechnology company, which engages in the business of discovering and developing drug candidates to selectively modulate the Wnt pathway, a critical mediator of tissue repair, in a broad range of organs and tissues. The company was founded by K. Christopher Garcia and Roeland Nusse on August 12, 2015 and is headquartered in South San Francisco, CA.

Surrozen Inc

Neutral Sentiment

<ul class="summary-bullets"><li>INDP’s rally followed a $24 million share sale, with proceeds potentially supporting early research into a sleep-related device.</li><li>Former biotech CYPH gained as its Zcash mining operation added 3,023 ZEC to its treasury.</li><li>MNOV completed patient visits in the blinded portion of its ALS trial, while a favorable FDA advisory panel vote lifted attention on GRAL’s Galleri test.</li></ul>Moderna, Inc. (MRNA) is on track to become September’s second-best performer in the S&amp;P 500, but five smaller stocks have delivered even larger gains this month, driven by developments ranging from an impending ALS trial readout to a cancer-test regulatory review, and, in one case, a Zcash strategy.<a href="https://stocktwits.com/symbol/MRNA">Moderna (MRNA)</a> is up about 39% so far this month. Among stocks with market caps above $100 million,&nbsp;<a href="https://stocktwits.com/symbol/INDP">Indaptus Therapeutics (INDP)</a> has surged about 249%, followed by&nbsp;<a href="https://stocktwits.com/symbol/CYPH">Cypherpunk Technologies (CYPH)</a> at 124%,&nbsp;<a href="https://stocktwits.com/symbol/MNOV">MediciNova (MNOV)</a> at 85%,&nbsp;<a href="https://stocktwits.com/symbol/GRAL">GRAIL (GRAL)</a> at 58% and&nbsp;<a href="https://stocktwits.com/symbol/SRZN">Surrozen (SRZN)</a> at 53%.&nbsp;<img src="https://news.stocktwits-cdn.com/mrna_rally_c347f1f47e.png" alt="mrna rally.png"><h2 class="st-heading-2">Moderna’s Phase 3 Win Faces Its Next Test&nbsp;</h2>The foundation for Moderna’s rally was laid in August, when the company and partner Merck announced that their Phase 3 trial of personalized cancer vaccine Intismeran autogene plus Keytruda met its primary endpoint in patients whose melanoma had been surgically removed. The companies also reported success on a key secondary endpoint, but have not yet presented the detailed trial results.This week, Moderna gave investors a date for that closer examination: the Phase 3 findings will be presented at a Presidential Symposium on Oct.24 during the European Society for Medical Oncology congress.&nbsp;At a recent Bernstein healthcare conference, CEO Stéphane Bancel said, “Moderna has been, since day one, an mRNA platform company,” calling intismeran “only our first oncology product.” Moderna and Merck have nine studies ongoing, he said, but they still must test the potential for the treatment to work in other cancers. Chief development officer David Berman said he was “very confident that we have a strong case for approval” in melanoma.&nbsp;Stocktwits sentiment for MRNA was ‘extremely bullish’ a month ago, slipped to ‘bearish’ a week ago and recovered to ‘bullish’ on Thursday before returning to ‘extremely bullish’ in the latest reading. Over the month, message volume rose 336% and the ticker’s watcher base grew 5%.&nbsp;<figure class="image"><img src="https://news.stocktwits-cdn.com/mrna_ss_b81951629d.png" alt="mrna ss.png" width="645" height="355"><figcaption>MRNA sentiment and message volume as of September 24 | Source: Stocktwits</figcaption></figure><h2 class="st-heading-2">INDP Surges On $24M Financing&nbsp;</h2>Indaptus Therapeutics has delivered the largest September gain of the group as investors assess a possible new direction for the company. Last month, Indaptus said it had stopped enrolling patients in its Decoy20 cancer study and had no active clinical development programs. However, earlier this month the company announced a financing deal and disclosed plans to explore a neurotechnology device for certain sleep-related conditions, with a potential future FDA submission in view.&nbsp;The firm also agreed to sell 20.3 million shares at $1.18 each in a private placement expected to raise about $24 million. The price was about 1% above the deal’s Nasdaq pricing benchmark, though about 3% below INDP’s close before the agreement.&nbsp;Stocktwits sentiment for INDP shifted from ‘bullish’ a month ago to ‘bearish’ a week ago and remained ‘bearish’ in the latest reading. The ticker’s watcher base edged up 0.3% over the month.&nbsp;<figure class="image"><img src="https://news.stocktwits-cdn.com/indp_ss_9ade02b797.png" alt="indp ss.png" width="640" height="344"><figcaption>INDP sentiment and message volume as of September 24 | Source: Stocktwits</figcaption></figure><h2 class="st-heading-2">CYPH Rallies As Zcash Mining Adds To Treasury&nbsp;</h2>Cypherpunk Technologies, previously known as Leap Therapeutics, changed its name and ticker last year to reflect a Zcash-based strategy. Its remaining cancer-drug operations sit within a Leap Therapeutics unit.&nbsp;Cypherpunk announced this week the launch of a 4.2 GSol/s Zcash mining fleet and said the operation had generated 3,023.13 ZEC in its first weeks, with the coins added to its treasury. The company had previously reported holdings of 323,394.38 ZEC as of Aug. 11.&nbsp;Stocktwits sentiment for CYPH remained ‘extremely bullish’ throughout the past month, though its score eased from (91/100) to (79/100). Over the same period, message volume surged 5,200%, and the ticker’s watcher base grew 4%.&nbsp;<figure class="image"><img src="https://news.stocktwits-cdn.com/cyph_ss_d24fe58448.png" alt="cyph ss.png" width="629" height="343"><figcaption>CYPH sentiment and message volume as of September 24 | Source: Stocktwits</figcaption></figure><h2 class="st-heading-2">MNOV Gains Ahead Of Year-End ALS Results&nbsp;</h2>MediciNova has climbed as investors look ahead to results from its Phase 2b/3 Combat-ALS trial of MN-166, or ibudilast. On Thursday, the company said the final patient had completed the last visit in the trial’s blinded portion. The study randomized 234 participants, and MediciNova expects to report topline findings by year-end. Its primary endpoint combines measures of function and survival. CEO Yuichi Iwaki said the company’s focus had shifted to “database lock and rigorous analysis of the study data.”&nbsp;Stocktwits sentiment for MNOV rose from ‘bullish’ a month ago to ‘extremely bullish’ a week ago, but has since fallen back through ‘bullish’ to ‘bearish’ in the latest reading. The ticker’s watcher base grew 0.6% over the month.&nbsp;<figure class="image"><img src="https://news.stocktwits-cdn.com/mnov_ss_84eff47815.png" alt="mnov ss.png" width="646" height="353"><figcaption>MNOV sentiment and message volume as of September 24 | Source: Stocktwits</figcaption></figure><h2 class="st-heading-2">GRAIL’s Galleri Wins A Favorable Panel Vote&nbsp;</h2>GRAIL’s September catalyst was a recent FDA advisory committee meeting on Galleri, its blood test intended to detect signals associated with multiple cancers in adults aged 50 and older. The panel&nbsp;<a href="https://stocktwits.com/news-articles/markets/equity/gral-s-galleri-cancer-test-clears-fda-panel-safety-vote-splits-on-effectiveness/cZM4avyRBBh">voted</a> 10-0 in support of the test’s safety, 6-4 on effectiveness, and 7-2, with one abstention, that its benefits outweighed its risks. Galleri is intended to be used alongside existing recommended cancer screenings, not as a replacement.&nbsp;The favorable votes advanced GRAIL’s case, but the FDA has yet to decide whether to approve the test and is not bound by the panel’s recommendation.Stocktwits sentiment for GRAIL shifted from ‘bullish’ a month ago to ‘bearish’ a week ago, then surged to ‘extremely bullish’ in the latest reading. The ticker’s watcher base grew 1% over the month.&nbsp;<figure class="image"><img src="https://news.stocktwits-cdn.com/grail_ss_65154b4dbf.png" alt="grail ss.png" width="651" height="351"><figcaption>GRAL sentiment and message volume as of September 24 | Source: Stocktwits</figcaption></figure><h2 class="st-heading-2">SRZN’s Eye-Drug Filing Sets Up Clinical Trial&nbsp;</h2>Surrozen submitted an investigational new drug application earlier this month for SZN-8141, an experimental antibody for diabetic macular edema. The treatment will combine activation of the Wnt pathway with inhibition of VEGF, a target already used in retinal-disease treatments. The company aims to begin an early-stage study by year-end, subject to regulatory clearance, and expects initial data in the second half of 2027.&nbsp;Stocktwits sentiment for SRZN moved from ‘neutral’ a month ago to ‘bullish’ a week ago, dipped to ‘bearish’ on Thursday, then rebounded to ‘extremely bullish’ in the latest reading. Over the month, message volume rose 50%, and the ticker’s watcher base edged up 0.1%.&nbsp;<figure class="image"><img src="https://news.stocktwits-cdn.com/srzn_ss_4bd078b953.png" alt="srzn ss.png" width="633" height="348"><figcaption>SRZN sentiment and message volume as of September 24 | Source: Stocktwits</figcaption></figure>Year to date, MRNA has surged about 561%, followed by CYPH at 252%, MNOV at 102%, SRZN at 49%, GRAL at 46% and INDP at 37%.&nbsp;For updates and corrections, email newsroom[at]stocktwits[dot]com.Read Next:&nbsp;<a href="https://stocktwits.com/news-articles/markets/equity/bb-stock-qnx-royalties-star-of-the-show-president-holdings-revealed/cZMarhGRBad">BB Stock Eyes Best Week In 3 Months As QNX Royalties Become ‘Star Of The Show’ — President’s Holdings Revealed&nbsp;</a>

In this photo illustration, the American pharmaceutical and biotechnology company Moderna logo is displayed on a smartphone screen. (Photo Illustration by Budrul Chukrut/SOPA Images/LightRocket via Getty Images)

Cypherpunk Technologies Inc.

GRAIL Inc.

iShares Biotechnology ETF

Indaptus Therapeutics Inc

Medicinova Inc

Moderna Inc

SPDR S&P Biotech ETF

Health Care Select Sector SPDR Fund

Hold rates steady

Cut 25 bps

Hike 25 bps

Fed decision day is here - Kevin Warsh chairs his first FOMC meeting with markets pricing a hold at 3.50%-3.75% but watching for a hawkish shift. Vote on what you expect to be decided today, then drop your prediction for the first rate cut or hike in the comments.

What do you expect the Fed to decide at its FOMC meeting today? 
 
Drop a comment with when you expect the first cut/hike to be.

Current Price	$25.14
Prev Close	$23.84
Open	$23.74
Dividend Yield	0.00%
50-Day Moving Average	$23.71
Beta	0.78
Avg. Volume	893,620.75
PE Ratio	-0.54

52-Week High	$37.83
52-Week Low	$11.39
Market Capitalization	$280.2M
EPS (Annual)	-$32.37
Price to Book	-1.28
Revenue Per Employee	$79,022.73

Feed

News

Sentiment

Earnings

Fundamentals

Info

SRZN Fundamentals